Aesica Recruits Operations Director in Formulated Products Business Unit
News Feb 05, 2013
Aesica has appointed Jarrett Palmer as Operations Director of its formulated products business unit business.
Palmer has accumulated over 15 years’ experience in senior leadership positions and has managed facilities for global CMOs including Catalent Pharma Solutions and Piramal Healthcare.
Based at Aesica headquarters in Newcastle (UK), Palmer will report to Chris Gowland , Managing Director of Formulated Products.
Operations at the Queenborough facility (UK) and recently acquired sites in Europe - including Monheim and Zwickau (Germany) and Pianezza (Italy) - will be managed by Palmer who will coordinate operational activities around the company’s commercial scale manufacturing, packaging and distribution activities.
Pivotal to this new role is the continued sustainable growth of Aesica, which includes continuous improvement to drive manufacturing efficiency and managing growing demand for potent manufacturing from the company’s UK base.
“We are delighted to have Jarrett Palmer join Aesica as Operations Director. He brings significant experience with a long and established track record of managing sites for global CMOs. Jarrett’s role is central to the maintenance of high standards at our FDA approved commercial scale manufacturing sites. He will be critical to the acquisition process and will support senior management in identifying global acquisition targets and transitioning new sites in line with our exacting efficiency and quality standards”, commented Chris Gowland Managing Director of Formulated Products at Aesica.
“Aesica is one of the most exciting names in contract manufacturing at the moment”, added Palmer on his decision to join the company. “It has big plans for growth which will significantly increase its global footprint and its manufacturing and packaging capacity at commercial scale, which is what the market has a great demand for. The prospect of being at the heart of this dynamic business is what attracted me to Aesica. My goal is to ensure that at every step, we optimize our internal infrastructure so that our customers enjoy responsiveness and efficiency in all interaction with us.”
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018